Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1648 other investors.
Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst.
Redeye leaves a more elaborate take on Genovis following its Q3 2022 report. We are left with a positive bias after yesterday's report and make minor adjustments to our forecasts, resulting in an updated fair value range.
Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our EBIT estimate.
Redeye returns with a follow-up note to Genovis’ Q2’22 report. We see a relatively weak report, although the growth in the Analytics segment (+31%) was a positive element.
Redeye provides its initial take on Genovis’ Q2’22 report, which came in below our expectations. We consider this a rather weak report from Genovis, although we note that the Analytics segment is continuing to grow solidly (+31%).
Redeye endorses Genovis entering into a service agreement with evitria AG for LC-MS analysis of recombinant antibodies.
Redeye returns with a follow-up note to Genovis’ Q1’22 report. We are encouraged to see that the company is reporting yet another solid quarter and that the growth remains high, particularly in the Enzyme business.
Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business.
Top Picks increases one of its largest positions even further, following solid operational development and a falling stock price. Our cash position will be about 9% after the transaction. Top Picks is a model portfolio by Redeye.
Redeye returns with a follow-up note to Genovis’ Q4’21 report. We are encouraged to see that Genovis is returning with higher growth and believe that the company has strong growth prospects in 2022 and onwards.